Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Corynanthine is a naturally occurring yohimban alkaloid found in the Rauvolfia and Corynanthe (including Pausinystalia) genera of plants[1][3][7]. It is one of two diastereoisomers of yohimbine, the other being rauwolscine[1][7]. Corynanthine functions pharmacologically primarily as a selective alpha-1-adrenergic receptor antagonist, showing approximately tenfold higher affinity for these receptors than for alpha-2-adrenergic receptors[1][5][11]. This contrasts with yohimbine and rauwolscine, which are more selective for the alpha-2-adrenergic receptor. The result is that corynanthine is not a stimulant, but instead acts as a depressant and is thought to contribute to the antihypertensive effects of certain Rauvolfia extracts[1][5][11]. It also has some reported activity at serotonin receptors[1] and has been shown experimentally to decrease intraocular pressure in animal studies[11][12].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on corynanthine.